These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 30269615)

  • 1. Drug pharmacomicrobiomics and toxicomicrobiomics: from scattered reports to systematic studies of drug-microbiome interactions.
    Aziz RK; Hegazy SM; Yasser R; Rizkallah MR; ElRakaiby MT
    Expert Opin Drug Metab Toxicol; 2018 Oct; 14(10):1043-1055. PubMed ID: 30269615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the gut microbiome to control drug pharmacomicrobiomics: the next frontier in oral drug delivery.
    Kamath S; Stringer AM; Prestidge CA; Joyce P
    Expert Opin Drug Deliv; 2023; 20(10):1315-1331. PubMed ID: 37405390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of gut microbiota on drug metabolism and toxicity.
    Li H; He J; Jia W
    Expert Opin Drug Metab Toxicol; 2016; 12(1):31-40. PubMed ID: 26569070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
    Sharma A; Buschmann MM; Gilbert JA
    Clin Pharmacol Ther; 2019 Aug; 106(2):317-328. PubMed ID: 30937887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut Reactions: Breaking Down Xenobiotic-Microbiome Interactions.
    Clarke G; Sandhu KV; Griffin BT; Dinan TG; Cryan JF; Hyland NP
    Pharmacol Rev; 2019 Apr; 71(2):198-224. PubMed ID: 30890566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bringing pharmacomicrobiomics to the clinic through well-designed studies.
    Steiner HE; Patterson HK; Giles JB; Karnes JH
    Clin Transl Sci; 2022 Oct; 15(10):2303-2315. PubMed ID: 35899413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut microbiota: what is its place in pharmacology?
    Tarasiuk A; Fichna J
    Expert Rev Clin Pharmacol; 2019 Oct; 12(10):921-930. PubMed ID: 31544557
    [No Abstract]   [Full Text] [Related]  

  • 8. Omics for Understanding the Gut-Liver-Microbiome Axis and Precision Medicine.
    Khalsa J; Duffy LC; Riscuta G; Starke-Reed P; Hubbard VS
    Clin Pharmacol Drug Dev; 2017 Mar; 6(2):176-185. PubMed ID: 28263462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacomicrobiomics and Drug-Infection Interactions: The Impact of Commensal, Symbiotic and Pathogenic Microorganisms on a Host Response to Drug Therapy.
    Torres-Carrillo N; Martínez-López E; Torres-Carrillo NM; López-Quintero A; Moreno-Ortiz JM; González-Mercado A; Gutiérrez-Hurtado IA
    Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between drugs and the gut microbiome.
    Weersma RK; Zhernakova A; Fu J
    Gut; 2020 Aug; 69(8):1510-1519. PubMed ID: 32409589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacomicrobiomics: a novel route towards personalized medicine?
    Doestzada M; Vila AV; Zhernakova A; Koonen DPY; Weersma RK; Touw DJ; Kuipers F; Wijmenga C; Fu J
    Protein Cell; 2018 May; 9(5):432-445. PubMed ID: 29705929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacomicrobiomics informs clinical pharmacogenomics.
    Katsila T; Balasopoulou A; Tsagaraki I; Patrinos GP
    Pharmacogenomics; 2019 Jul; 20(10):731-739. PubMed ID: 31368841
    [No Abstract]   [Full Text] [Related]  

  • 13. Toxicomicrobiomics: The Human Microbiome vs. Pharmaceutical, Dietary, and Environmental Xenobiotics.
    Abdelsalam NA; Ramadan AT; ElRakaiby MT; Aziz RK
    Front Pharmacol; 2020; 11():390. PubMed ID: 32372951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomics in pharmacology - a delve into the novel field of pharmacometabolomics.
    Mussap M; Loddo C; Fanni C; Fanos V
    Expert Rev Clin Pharmacol; 2020 Feb; 13(2):115-134. PubMed ID: 31958027
    [No Abstract]   [Full Text] [Related]  

  • 15. Drug response in association with pharmacogenomics and pharmacomicrobiomics: towards a better personalized medicine.
    Hassan R; Allali I; Agamah FE; Elsheikh SSM; Thomford NE; Dandara C; Chimusa ER
    Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33253350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics.
    ElRakaiby M; Dutilh BE; Rizkallah MR; Boleij A; Cole JN; Aziz RK
    OMICS; 2014 Jul; 18(7):402-14. PubMed ID: 24785449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Microbiome and Its Potential for Pharmacology.
    Chavira A; Belda-Ferre P; Kosciolek T; Ali F; Dorrestein PC; Knight R
    Handb Exp Pharmacol; 2019; 260():301-326. PubMed ID: 31820171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microbiota-drug interactions: Impact on metabolism and efficacy of therapeutics.
    Wilkinson EM; Ilhan ZE; Herbst-Kralovetz MM
    Maturitas; 2018 Jun; 112():53-63. PubMed ID: 29704918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Precision Medicine Goes Microscopic: Engineering the Microbiome to Improve Drug Outcomes.
    Lam KN; Alexander M; Turnbaugh PJ
    Cell Host Microbe; 2019 Jul; 26(1):22-34. PubMed ID: 31295421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-microbiota interactions: an emerging priority for precision medicine.
    Zhao Q; Chen Y; Huang W; Zhou H; Zhang W
    Signal Transduct Target Ther; 2023 Oct; 8(1):386. PubMed ID: 37806986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.